Pages that link to "Q420207"
Jump to navigation
Jump to search
The following pages link to capecitabine (Q420207):
Displaying 50 items.
- World Health Organization Model List of Essential Medicines (Q37155) (← links)
- breast cancer (Q128581) (← links)
- acenocoumarol (Q304088) (← links)
- invasive ductal carcinoma (Q1671685) (← links)
- rectum cancer (Q2739660) (← links)
- CAPOX (Q3648511) (← links)
- appendix cancer (Q4781026) (← links)
- bile duct carcinoma (Q11611688) (← links)
- large intestine cancer (Q12048781) (← links)
- gastrointestinal carcinoma (Q18553565) (← links)
- ampulla of Vater cancer (Q18553760) (← links)
- rectum adenocarcinoma (Q18554959) (← links)
- colon cancer (Q18555025) (← links)
- colon adenocarcinoma (Q18555055) (← links)
- rectosigmoid cancer (Q18555196) (← links)
- gastric adenocarcinoma (Q18556047) (← links)
- pancreatic adenocarcinoma (Q18556189) (← links)
- small intestine carcinoma (Q18556538) (← links)
- anal carcinoma (Q18556540) (← links)
- Capecitabine plus Irinotecan (XELIRI regimen) compared to 5-FU/LV plus Irinotecan (FOLFIRI regimen) as neoadjuvant treatment for patients with unresectable liver-only metastases of metastatic colorectal cancer: a randomised prospective phase II trial (Q21260391) (← links)
- Thymidylate synthetase (Q22676802) (← links)
- Capecitabine for ER-positive versus ER-negative breast cancer (Q24194664) (← links)
- Clinical management of localized colon cancer with capecitabine (Q24611758) (← links)
- Capecitabine in the management of colorectal cancer (Q24633039) (← links)
- Capecitabine monotherapy: review of studies in first-line HER-2-negative metastatic breast cancer (Q24633167) (← links)
- Phase I study of epirubicin, cisplatin and capecitabine plus matuzumab in previously untreated patients with advanced oesophagogastric cancer (Q24649684) (← links)
- The clinical and economic benefits of capecitabine and tegafur with uracil in metastatic colorectal cancer (Q24652904) (← links)
- Protocol of a randomised phase III clinical trial of sequential capecitabine or 5-fluorouracil plus bevacizumab (Cape/5-FU-Bmab) to capecitabine or 5-fluorouracil plus oxaliplatin plus bevacizumab (CapeOX/mFOLFOX6-Bmab) .. (Q24658529) (← links)
- Phase I study of intermittent and chronomodulated oral therapy with capecitabine in patients with advanced and/or metastatic cancer (Q25256709) (← links)
- Relationship between cyclooxygenase 8473T>C polymorphism and the risk of lung cancer: a case-control study (Q25257445) (← links)
- Efficacy of S-1 vs capecitabine for the treatment of gastric cancer: a meta-analysis (Q26865057) (← links)
- Incidence and relative risk of grade 3 and 4 diarrhoea in patients treated with capecitabine or 5-fluorouracil: a meta-analysis of published trials (Q27028095) (← links)
- Lapatinib plus capecitabine for HER2-positive advanced breast cancer (Q27851403) (← links)
- HER2 in high-risk rectal cancer patients treated in EXPERT-C, a randomized phase II trial of neoadjuvant capecitabine and oxaliplatin (CAPOX) and chemoradiotherapy (CRT) with or without cetuximab (Q27852594) (← links)
- Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissue (Q27863454) (← links)
- Effect of Neoadjuvant Chemoradiotherapy with Capecitabine versus Fluorouracil for Locally Advanced Rectal Cancer: A Meta-Analysis (Q28066866) (← links)
- Topical henna for capecitabine induced hand-foot syndrome (Q28250089) (← links)
- Ixabepilone plus capecitabine for metastatic breast cancer progressing after anthracycline and taxane treatment (Q28255226) (← links)
- Severe or lethal toxicities upon capecitabine intake: is DPYD genetic polymorphism the ideal culprit? (Q28257296) (← links)
- Anti-tumour efficacy of capecitabine in a genetically engineered mouse model of pancreatic cancer (Q28534413) (← links)
- Phase I Trial of Consolidative Radiotherapy with Concurrent Bevacizumab, Erlotinib and Capecitabine for Unresectable Pancreatic Cancer (Q28552089) (← links)
- Correlation of HER2, p95HER2 and HER3 expression and treatment outcome of lapatinib plus capecitabine in her2-positive metastatic breast cancer (Q28728701) (← links)
- Capecitabine Accord (Q29004946) (← links)
- Capecitabine Medac (Q29004947) (← links)
- Capecitabine Sun (Q29004949) (← links)
- Capecitabine Teva (Q29004950) (← links)
- Ecansya (Q29005760) (← links)
- Xeloda (Q29006685) (← links)
- Fluoropyrimidine activity (Q29883401) (← links)
- Capecitabine and radiation therapy for advanced gastrointestinal malignancies (Q30310400) (← links)